The acute respiratory distress syndrome (ARDS) is one of the most severe complications of the SARS-Cov-2 viral infection and other lung pathologies or infections. ARDS entails severe inflammation in the lungs resulting in certain parts of the lung being unusable and cause patients to require mechanical ventilation. A meta-analysis and systematic review conducted out of Sherbrooke Hospital in Quebec, Canada and published in 2019 evaluated the clinical effect of omega-3 polyunsaturated fatty acids on gas exchange and clinical outcomes in ARDS patients. 12 RCT’s (n=1280) were included in the study, all patients were in ICU and all studies compared the administration of omega-3 fatty acids to placebo. A significant improvement in the early PaO2-to-FiO2 ratio (PaO2 - arterial pressure of oxygen; an indication of the percent of oxygen that is being carried in the blood / FiO2 - fraction of inspired oxygen;  room air is approximately 21%, this number increases with more severe ARDS) which persisted at days 7 to 8, and a trend in those receiving ω-3 PUFA toward reduced ICU length of stay and duration of mechanical ventilation. An improvement in this ratio would consist of higher PaO2 and lower FiO2 vales. Whereas mortality, hospital length of stay and infectious complications remained unchanged. This research suggests that the implementation of omega-3 fatty acids may be a reasonable strategy to help as an adjuvant in the treatment of patients with ARDS.